Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Pre-Tax Margin
Income before tax as a percentage of revenue.
Entera Bio Ltd.NASDAQ: ENTX
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin not reported for Q1 FY2026
Over 3 fiscal years it narrowed by 17583.5 pp.
Context
- Pre-tax margin widened in 1 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -27235.7%
- Year-over-year change
- -21972.2pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -27235.7% | -21972.2pp |
| FY2024 | 2024-12-31 | -5263.5% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -9652.2% | -7507.6pp |
| FY2021 | 2021-12-31 | -2144.7% | — |
Pre-Tax Margin vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's FY2025 pre-tax margin of -27235.7% is the 6th highest of the 7 companies compared; the peer median is -680.2%.
- Its year-over-year change of -21972.2 pp is the 5th highest of 6, against a peer median of +96.8 pp.
- Over three fiscal years its change of -17583.5 pp compares with a peer median of +110.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 50.5% | +246.6 pp | +232.6 pp | |
| LTM Mar 2026 | 28.3% | +184.8 pp | +110.4 pp | |
| LTM Mar 2026 | -468.0% | +96.8 pp | +177.7 pp | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -892.4% | -462.9 pp | -395.0 pp |
| LTM Mar 2026 | -4088.8% | — | — | |
| FY2025 | -27235.7% | -21972.2 pp | -17583.5 pp | |
| FY2025 | -130000.0% | -80745.7 pp | -127273.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ENTX) | -680.2% | +96.8 pp | +110.4 pp | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 571K | 134K | 0 | 181K | 42K |
| Cost of Revenue | 373K | 165K | 56K | 172K | 42K |
| Gross Profit | 198K | (31K) | (56K) | 9K | 0 |
| Gross Margin | 34.7% | -23.1% | — | 5.0% | 0.0% |
| Research & Development | 6.77M | 5.78M | 4.45M | 4.5M | 6M |
| Selling, General & Admin | 5.69M | 7.25M | 4.43M | 5.1M | 5.53M |
| Operating Expenses | 12.42M | 13.04M | 8.88M | 9.59M | 11.53M |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| EBITDA | (12.16M) | (12.87M) | (8.8M) | (9.48M) | (11.41M) |
| EBITDA Margin | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% |
| Operating Income | (12.22M) | (13.07M) | (8.94M) | (9.59M) | (11.53M) |
| Operating Margin | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% |
| Interest Income | 0 | 83K | 31K | 58K | 0 |
| Interest Expense | 29K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (29K) | 134K | 80K | 58K | 90K |
| Income Before Tax | (12.25M) | (12.93M) | (8.86M) | (9.53M) | (11.44M) |
| Pre-Tax Margin | -2144.7% | -9652.2% | — | -5263.5% | -27235.7% |
| Income Tax Expense | (59K) | 137K | 29K | 14K | 0 |
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Net Margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (Basic) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| EPS (Diluted) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| Weighted Avg Shares | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
| Weighted Avg Shares (Diluted) | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.